Abstract
The MAT Act, the MATE Act and the TREATS Act are all in play now, designed to promote various forms of buprenorphine prescribing — some with specialized education, some without specialized education and some merely over the phone. Stay tuned for what is going to be a bumpy ride. The American Society of Addiction Medicine (ASAM) and the American Medical Association are all for freeing up their members from any kind of regulation. For its part, ASAM would like its trained and certified prescribers to have precedence. Everybody is pretty keen on the idea of getting fully reimbursed for doing something over the phone. Or maybe on video. The American Association for the Treatment of Opioid Dependence is concerned about patients. So is NAMA. What is clear, however, is that the x‐waiver itself, as it now stands, is doomed to extinction. The juggernaut against it is too great. Eight hours of training? No way, say doctors, we already have a Drug Enforcement Administration license and can prescribe Schedule II; buprenorphine is only Schedule III. We have covered the x‐waiver controversy in almost every issue this year. See our website for archived articles. More next week on TREATS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
